Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study.
acute kidney injury
antimicrobial stewardship
colistin
dosage
polymyxin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
19 Dec 2021
19 Dec 2021
Historique:
received:
30
11
2021
revised:
15
12
2021
accepted:
17
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients receiving intravenous colistin were included in the analyses. Inadequate colistin dosages were administered in 27% of cases (50/187). In multivariable analysis, AKI (dummy variable with KDIGO stage 0 as a reference, odds ratio (OR) 3.98 with 95% confidence interval (CI) 1.48-10.74 for stage 1, OR 4.44 with 95% CI 1.17-16.93 for stage 2, OR 9.41 with 95% CI 1.59-55.70 for stage 3; overall
Identifiants
pubmed: 34943767
pii: antibiotics10121554
doi: 10.3390/antibiotics10121554
pmc: PMC8698974
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2016 Dec 23;64(5):565-571
pubmed: 28011614
Sci Rep. 2018 Aug 10;8(1):11968
pubmed: 30097635
Antibiotics (Basel). 2019 Mar 14;8(1):
pubmed: 30875778
Expert Rev Clin Pharmacol. 2018 Dec;11(12):1219-1236
pubmed: 30444147
J Glob Antimicrob Resist. 2020 Mar;20:43-49
pubmed: 31207379
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
Adv Exp Med Biol. 2019;1145:219-249
pubmed: 31364081
Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):59-71
pubmed: 27573251
Expert Opin Pharmacother. 2021 Aug 17;:1-4
pubmed: 34399631
Pharmacol Rev. 2021 Apr;73(2):679-728
pubmed: 33627412
Expert Rev Anti Infect Ther. 2021 Jun 3;:1-17
pubmed: 34033499
Expert Opin Pharmacother. 2021 Feb;22(2):167-177
pubmed: 32915685